Stockscreener 앱 받기
13.11
4.45%
-0.61
시장 영업 전:
13.11
전일 마감가:
$13.72
열려 있는:
$13.75
하루 거래량:
2.02M
Relative Volume:
0.82
시가총액:
$325.06M
수익:
$82.71M
순이익/손실:
$-102.24M
주가수익비율:
-3.5722
EPS:
-3.67
순현금흐름:
$-76.57M
1주 성능:
-11.84%
1개월 성능:
+212.89%
6개월 성능:
+18.75%
1년 성능:
-23.69%
1일 변동 폭
$12.87
$13.75
1주일 범위
$12.87
$15.61
52주 변동 폭
$3.42
$18.15
Urogen Pharma Ltd Stock (URGN) Company Profile
명칭
Urogen Pharma Ltd
전화
972 9 770 7601
주소
9 HA'TA'ASIYA ST, RA'ANANA
URGN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
URGN
Urogen Pharma Ltd
|
13.11 | 325.06M | 82.71M | -102.24M | -76.57M | -3.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
443.40 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
521.00 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
318.25 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
560.04 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
254.49 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Urogen Pharma Ltd Stock (URGN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-16 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2025-05-22 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2025-04-16 | 개시 | Scotiabank | Sector Outperform |
| 2025-02-19 | 재개 | Ladenburg Thalmann | Buy |
| 2024-08-22 | 개시 | Guggenheim | Buy |
| 2023-02-08 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-04-27 | 개시 | Berenberg | Buy |
| 2020-04-16 | 재확인 | H.C. Wainwright | Buy |
| 2020-04-13 | 재확인 | H.C. Wainwright | Buy |
| 2020-01-09 | 개시 | National Securities | Neutral |
| 2019-05-30 | 개시 | JP Morgan | Neutral |
| 2019-05-29 | 개시 | Goldman | Neutral |
| 2019-01-29 | 개시 | H.C. Wainwright | Buy |
| 2018-11-08 | 재개 | Jefferies | Buy |
| 2018-04-04 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2018-01-02 | 개시 | Ladenburg Thalmann | Buy |
| 2017-11-15 | 재확인 | Oppenheimer | Outperform |
| 2017-11-15 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
모두보기
Urogen Pharma Ltd 주식(URGN)의 최신 뉴스
Urogen Pharma (NASDAQ:URGN) Short Interest Down 29.9% in May - Defense World
HC Wainwright Decreases Earnings Estimates for Urogen Pharma - Defense World
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of UroGen Pharma Ltd.URGN - FinancialContent
UroGen Pharma Ltd (NASDAQ: URGN) Stock: A Value Hunter’s Investment? - Stocksregister
H.C. Wainwright Sees Billion Dollar Potential in UroGen’s New Therapy - MSN
UroGen Pharma (NASDAQ:URGN) Sees Large Volume Increase Following Analyst Upgrade - Defense World
UroGen Pharma (NASDAQ:URGN) Upgraded to “Buy” at HC Wainwright - Defense World
UROGEN PHARMA LTD. (NASDAQ: URGN) SHAREHOLDER ALERT - GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Red Cat, Reckitt, UroGen and Fortrea and Encourages Investors to Contact the Firm - GlobeNewswire Inc.
UroGen Investor Drops Cancer Drug Suit Following FDA Approval - Bloomberg Law News
Investors who lost money on UroGen Pharma Ltd.(URGN) should contact Levi & Korsinsky about ... - Eagle-Tribune
Investors who lost money on UroGen Pharma Ltd.(URGN) should - GlobeNewswire
URGN SHAREHOLDER REPORT: UroGen Pharma Ltd. was Sued for - GlobeNewswire
Lost Money on UroGen Pharma Ltd. (URGN)? Contact Levi & Korsinsky Before July 28, 2025 to Join Class Action - ACCESS Newswire
URGN Investors Have Opportunity to Lead UroGen Pharma Ltd. Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
HC Wainwright Upgrades UroGen Pharma to Buy From Neutral, $50 Price Target - MarketScreener
UroGen Pharma Ltd. Class Action: The Gross Law Firm Reminds UroGen Pharma Ltd. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 28, 2025URGN - PR Newswire
Lost Money on UroGen Pharma Ltd. (URGN)? Urged to Join Class Action Before July 28, 2025Contact Levi & Korsinsky - ACCESS Newswire
URGN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that UroGen Pharma Ltd. Investors Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in UroGen Pharma Ltd. of Class Action Lawsuit and Upcoming Deadlines - GlobeNewswire Inc.
Scotiabank Raises UroGen Pharma (NASDAQ:URGN) Price Target to $47.00 - Defense World
UroGen Pharma (NASDAQ:URGN) Stock Price Expected to Rise, Guggenheim Analyst Says - Defense World
UroGen Pharma (NASDAQ:URGN) Shares Gap Up After Analyst Upgrade - Defense World
URGN INVESTOR NOTICE: UroGen Pharma Ltd. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit - Kilgore News Herald
UroGen Pharma Ltd. (URGN) Faces Securities Class Action - GlobeNewswire
URGN INVESTOR DEADLINE: UroGen Pharma Ltd. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - The Victoria Advocate
Goldman Sachs Increases Price Target for UroGen Pharma (URGN) Af - GuruFocus
UroGen Pharma Gains Amid Analyst Ratings in Biopharma Sector Russell 1000 - Kalkine Media
UroGen Pharma price target raised to $31 from $10 at Oppenheimer - Investing.com India
UroGen Gets A First-Ever Bladder Cancer Approval Despite US FDA AdComm ‘No’ Vote - insights.citeline.com
UroGen Pharma (URGN) Receives Price Target Boost to $31 After Zusduri Approval | URGN Stock News - GuruFocus
Why UroGen Pharma (URGN) Stock Is Skyrocketing This Week - Benzinga
UroGen Pharma (URGN) Sees Price Target Doubled by Scotiabank | URGN Stock News - GuruFocus
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff - GlobeNewswire
UroGen Pharma: Lessons Learned And Future Outlook (NASDAQ:URGN) - Seeking Alpha
Scotiabank Boosts UroGen Pharma (URGN) Price Target Amid FDA Opt - GuruFocus
Zusduri flurry ends; ‘set up’ at ODAC, Urogen prevails with FDA - BioWorld MedTech
UroGen Pharma (URGN) Soars After FDA Approval and Price Target B - GuruFocus
Why Is UroGen Pharma Stock Trading Higher On Friday?UroGen Pharma (NASDAQ:URGN) - Benzinga
Scotiabank Boosts UroGen Pharma (URGN) Price Target Amid FDA Optimism | URGN Stock News - GuruFocus
UroGen Pharma (URGN) Stock Outlook: Guggenheim Raises Price Target | URGN Stock News - GuruFocus
URGN Investors Have the Opportunity to Lead the UroGen Securities Fraud Lawsuit with Faruqi & Faruqi, LLP - StreetInsider
UroGen Soars On Price Target Upgrade On Heels Of FDA Approval For Cancer Medicine: Retail Sees Stock Touching $20 - Asianet Newsable
UroGen continues to climb after bladder cancer drug approval - Seeking Alpha
Transcript : UroGen Pharma Ltd.Special Call - marketscreener.com
UroGen's Zusduri wins FDA's blessing as first therapy for certain bladder cancer patients, despite negative adcomm vote - Fierce Pharma
UroGen Pharma (NASDAQ:URGN) Given “Buy” Rating at D. Boral Capital - Defense World
UroGen Pharma stock soars as FDA approves Zusduri despite negative panel vote - Investing.com India
FDA approves UroGen Pharma’s bladder cancer treatment - Investing.com
UroGen Pharma stock price target raised to $47 from $23 at Scotiabank - Investing.com
Guggenheim Boosts UroGen Pharma (URGN) Price Target Following FDA Approval | URGN Stock News - GuruFocus
Urogen Pharma Ltd (URGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.02%
1.78%
자본화:
|
볼륨(24시간):